Endo begins Mersana's foray into antibody-drug conjugates with $270 million deal
This article was originally published in Scrip
Executive Summary
Mersana Therapeutics announced a collaboration agreement with Endo Pharmaceuticals worth up to $270 million plus royalties, its first deal in antibody-drug conjugates (ADCs).
You may also be interested in...
VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs
During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.